5,5'-diphenylhydantoin decreases specific 3,5,3'-triiodothyronine (T3) binding by rat hepatic nuclear T3 receptors

D. N. Mann, Martin I. Surks

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

The influence of 5,5'-diphenylhydantoin (DPH) on specific T3 binding by rat hepatic nuclear T3 receptors was determined in tissue obtained from euthyroid and athyreotic rats. Nuclear binding of [125I]T3 was determined in isolated liver nuclei 60 min after the injection of DPH (20 mg/100 g BW) or vehicle (V). Mean specific nuclear T3 binding was decreased 14% (P < 0.01) and 24% (P < 0.02) from the control value in two experiments with nuclei from euthyroid rats and 23% (P < 0.02) in nuclei from athyreotic rats. These findings in athyreotic rats and the observation that endogenous nuclear T3 was not increased in euthyroid rats after DPH injection suggested that the observed decrease in specific T3 binding after DPH injection did not result from displacement of endogenous T3 from plasma proteins or other binding sites into the nucleus. Further studies employing isolated nuclei revealed that the DPH-induced decrease in specific nuclear T3 binding appeared independent of duration of incubation up to 90 min and dose related. Maximum inhibition of specific T3 binding was 14.0% (P < 0.001) and occurred in incubates that contained 320 μM DPH. Moreover, this DPH effect was evident throughout the full range of receptor saturation by T3. Similar effects of DPH were observed in studies using solubilized nuclear T3 receptors. A mean 14.0% decrement (P < 0.001) in specific T3 binding was observed throughout the 72-h time course of these studies. Moreover, the DPH-induced changes occurred when solubilized receptors were up to 62% saturated with T3. These studies show that DPH injection or addition in vitro results in a 10-20% decrease in specific T3 binding by isolated hepatic nuclei or solubilized hepatic neclear T3 receptors. This effect of DPH may result from a relatively weak interaction at nuclear sites and the very high concentration of DPH compared to T3 that prevails in DPH-treated animals.

Original languageEnglish (US)
Pages (from-to)1723-1731
Number of pages9
JournalEndocrinology
Volume112
Issue number5
StatePublished - 1983

Fingerprint

Thyroid Hormone Receptors
Phenytoin
Triiodothyronine
Cytoplasmic and Nuclear Receptors
Liver
Injections
Blood Proteins

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism

Cite this

5,5'-diphenylhydantoin decreases specific 3,5,3'-triiodothyronine (T3) binding by rat hepatic nuclear T3 receptors. / Mann, D. N.; Surks, Martin I.

In: Endocrinology, Vol. 112, No. 5, 1983, p. 1723-1731.

Research output: Contribution to journalArticle

@article{ca615e960d154b8fb4aa3c0deb08cc00,
title = "5,5'-diphenylhydantoin decreases specific 3,5,3'-triiodothyronine (T3) binding by rat hepatic nuclear T3 receptors",
abstract = "The influence of 5,5'-diphenylhydantoin (DPH) on specific T3 binding by rat hepatic nuclear T3 receptors was determined in tissue obtained from euthyroid and athyreotic rats. Nuclear binding of [125I]T3 was determined in isolated liver nuclei 60 min after the injection of DPH (20 mg/100 g BW) or vehicle (V). Mean specific nuclear T3 binding was decreased 14{\%} (P < 0.01) and 24{\%} (P < 0.02) from the control value in two experiments with nuclei from euthyroid rats and 23{\%} (P < 0.02) in nuclei from athyreotic rats. These findings in athyreotic rats and the observation that endogenous nuclear T3 was not increased in euthyroid rats after DPH injection suggested that the observed decrease in specific T3 binding after DPH injection did not result from displacement of endogenous T3 from plasma proteins or other binding sites into the nucleus. Further studies employing isolated nuclei revealed that the DPH-induced decrease in specific nuclear T3 binding appeared independent of duration of incubation up to 90 min and dose related. Maximum inhibition of specific T3 binding was 14.0{\%} (P < 0.001) and occurred in incubates that contained 320 μM DPH. Moreover, this DPH effect was evident throughout the full range of receptor saturation by T3. Similar effects of DPH were observed in studies using solubilized nuclear T3 receptors. A mean 14.0{\%} decrement (P < 0.001) in specific T3 binding was observed throughout the 72-h time course of these studies. Moreover, the DPH-induced changes occurred when solubilized receptors were up to 62{\%} saturated with T3. These studies show that DPH injection or addition in vitro results in a 10-20{\%} decrease in specific T3 binding by isolated hepatic nuclei or solubilized hepatic neclear T3 receptors. This effect of DPH may result from a relatively weak interaction at nuclear sites and the very high concentration of DPH compared to T3 that prevails in DPH-treated animals.",
author = "Mann, {D. N.} and Surks, {Martin I.}",
year = "1983",
language = "English (US)",
volume = "112",
pages = "1723--1731",
journal = "Endocrinology",
issn = "0013-7227",
publisher = "The Endocrine Society",
number = "5",

}

TY - JOUR

T1 - 5,5'-diphenylhydantoin decreases specific 3,5,3'-triiodothyronine (T3) binding by rat hepatic nuclear T3 receptors

AU - Mann, D. N.

AU - Surks, Martin I.

PY - 1983

Y1 - 1983

N2 - The influence of 5,5'-diphenylhydantoin (DPH) on specific T3 binding by rat hepatic nuclear T3 receptors was determined in tissue obtained from euthyroid and athyreotic rats. Nuclear binding of [125I]T3 was determined in isolated liver nuclei 60 min after the injection of DPH (20 mg/100 g BW) or vehicle (V). Mean specific nuclear T3 binding was decreased 14% (P < 0.01) and 24% (P < 0.02) from the control value in two experiments with nuclei from euthyroid rats and 23% (P < 0.02) in nuclei from athyreotic rats. These findings in athyreotic rats and the observation that endogenous nuclear T3 was not increased in euthyroid rats after DPH injection suggested that the observed decrease in specific T3 binding after DPH injection did not result from displacement of endogenous T3 from plasma proteins or other binding sites into the nucleus. Further studies employing isolated nuclei revealed that the DPH-induced decrease in specific nuclear T3 binding appeared independent of duration of incubation up to 90 min and dose related. Maximum inhibition of specific T3 binding was 14.0% (P < 0.001) and occurred in incubates that contained 320 μM DPH. Moreover, this DPH effect was evident throughout the full range of receptor saturation by T3. Similar effects of DPH were observed in studies using solubilized nuclear T3 receptors. A mean 14.0% decrement (P < 0.001) in specific T3 binding was observed throughout the 72-h time course of these studies. Moreover, the DPH-induced changes occurred when solubilized receptors were up to 62% saturated with T3. These studies show that DPH injection or addition in vitro results in a 10-20% decrease in specific T3 binding by isolated hepatic nuclei or solubilized hepatic neclear T3 receptors. This effect of DPH may result from a relatively weak interaction at nuclear sites and the very high concentration of DPH compared to T3 that prevails in DPH-treated animals.

AB - The influence of 5,5'-diphenylhydantoin (DPH) on specific T3 binding by rat hepatic nuclear T3 receptors was determined in tissue obtained from euthyroid and athyreotic rats. Nuclear binding of [125I]T3 was determined in isolated liver nuclei 60 min after the injection of DPH (20 mg/100 g BW) or vehicle (V). Mean specific nuclear T3 binding was decreased 14% (P < 0.01) and 24% (P < 0.02) from the control value in two experiments with nuclei from euthyroid rats and 23% (P < 0.02) in nuclei from athyreotic rats. These findings in athyreotic rats and the observation that endogenous nuclear T3 was not increased in euthyroid rats after DPH injection suggested that the observed decrease in specific T3 binding after DPH injection did not result from displacement of endogenous T3 from plasma proteins or other binding sites into the nucleus. Further studies employing isolated nuclei revealed that the DPH-induced decrease in specific nuclear T3 binding appeared independent of duration of incubation up to 90 min and dose related. Maximum inhibition of specific T3 binding was 14.0% (P < 0.001) and occurred in incubates that contained 320 μM DPH. Moreover, this DPH effect was evident throughout the full range of receptor saturation by T3. Similar effects of DPH were observed in studies using solubilized nuclear T3 receptors. A mean 14.0% decrement (P < 0.001) in specific T3 binding was observed throughout the 72-h time course of these studies. Moreover, the DPH-induced changes occurred when solubilized receptors were up to 62% saturated with T3. These studies show that DPH injection or addition in vitro results in a 10-20% decrease in specific T3 binding by isolated hepatic nuclei or solubilized hepatic neclear T3 receptors. This effect of DPH may result from a relatively weak interaction at nuclear sites and the very high concentration of DPH compared to T3 that prevails in DPH-treated animals.

UR - http://www.scopus.com/inward/record.url?scp=0020508544&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0020508544&partnerID=8YFLogxK

M3 - Article

VL - 112

SP - 1723

EP - 1731

JO - Endocrinology

JF - Endocrinology

SN - 0013-7227

IS - 5

ER -